Nelfinavir: a review of its use in the management of HIV infection (Q36286228)

13 August 2017

1 reference

title

Nelfinavir: a review of its use in the management of HIV infection (English)

1 reference

13 August 2017

0 references

1 reference

1

Caroline M Perry

1 reference

13 August 2017

James E Frampton

2

1 reference

13 August 2017

Paul L McCormack

series ordinal

3

1 reference

13 August 2017

M Asif A Siddiqui

series ordinal

4

1 reference

13 August 2017

Risto S Cvetković

series ordinal

5

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

65

1 reference

13 August 2017

2209-2244

1 reference

13 August 2017

15

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565150-00015

13 August 2017

0 references

cites work

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565150-00015

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

12 December 2020

Efavirenz liquid formulation in human immunodeficiency virus-infected children

1 reference

12 December 2020

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

12 December 2020

A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102).

1 reference

12 December 2020

Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir

1 reference

12 December 2020

Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

1 reference

12 December 2020

A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers

1 reference

12 December 2020

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

12 December 2020

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial

1 reference

12 December 2020

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir

1 reference

12 December 2020

The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir

1 reference

12 December 2020

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

1 reference

12 December 2020

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials

1 reference

12 December 2020

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

1 reference

12 December 2020

R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen

1 reference

12 December 2020

No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.

1 reference

12 December 2020

Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels

1 reference

12 December 2020

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

1 reference

12 December 2020

Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy

1 reference

12 December 2020

Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.

1 reference

12 December 2020

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

1 reference

12 December 2020

L-Glutamine Supplementation Improves Nelfinavir-Associated Diarrhea in HIV-Infected Individuals

1 reference

12 December 2020

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts

1 reference

12 December 2020

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

1 reference

12 December 2020

Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

12 December 2020

Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy

1 reference

12 December 2020

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

1 reference

12 December 2020

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

12 December 2020

Risk of birth defects associated with nelfinavir exposure during pregnancy

1 reference

12 December 2020

Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Nelfinavir and nevirapine side effects during pregnancy

1 reference

12 December 2020

Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors

1 reference

12 December 2020

Nelfinavir plasma concentrations are low during pregnancy

1 reference

12 December 2020

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients

1 reference

12 December 2020

A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.

1 reference

12 December 2020

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

1 reference

12 December 2020

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

1 reference

12 December 2020

HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

12 December 2020

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

1 reference

12 December 2020

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

1 reference

12 December 2020

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients

1 reference

12 December 2020

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

1 reference

12 December 2020

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

12 December 2020

Lopinavir/r versus nelfinavir as salvage therapy

1 reference

12 December 2020

Nelfinavir: an update on its use in HIV infection

1 reference

12 December 2020

A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients

1 reference

12 December 2020

Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects

1 reference

12 December 2020

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

1 reference

12 December 2020

Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Dynamic correlation of apoptosis and immune activation during treatment of HIV infection

1 reference

12 December 2020

Transplacental passage of protease inhibitors at delivery

1 reference

12 December 2020

Potential for interactions between caspofungin and nelfinavir or rifampin

1 reference

12 December 2020

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

1 reference

12 December 2020

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors

1 reference

12 December 2020

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

1 reference

12 December 2020

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

1 reference

12 December 2020

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

1 reference

12 December 2020

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

12 December 2020

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

1 reference

12 December 2020

Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.

1 reference

12 December 2020

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

1 reference

12 December 2020

A trial of three antiretroviral regimens in HIV-1-infected children

1 reference

12 December 2020

Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene

1 reference

12 December 2020

Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases

1 reference

12 December 2020

Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series

1 reference

12 December 2020

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

1 reference

12 December 2020

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

1 reference

12 December 2020

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

1 reference

12 December 2020

Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy

1 reference

12 December 2020

The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe

1 reference

12 December 2020

Hepatotoxicity and nelfinavir: a meta-analysis

1 reference

12 December 2020

Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir

1 reference

12 December 2020

The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

1 reference

12 December 2020

Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations

1 reference

12 December 2020

A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients

1 reference

12 December 2020

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.

1 reference

12 December 2020

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

1 reference

12 December 2020

Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

1 reference

12 December 2020

AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients

1 reference

12 December 2020

Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects

1 reference

12 December 2020

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

12 December 2020

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

12 December 2020

Efficacy of a nelfinavir- and nevirapine-containing salvage regimen

1 reference

12 December 2020

Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy

1 reference

12 December 2020

European guidelines for the clinical management and treatment of HIV-infected adults in Europe

1 reference

12 December 2020

10.2165/00003495-200565150-00015

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference